Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lorenzo Zanetto has a total of 84 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bronchopulmonary dysplasia and prematurity-associated lung disease: emerging therapies to improve lifelong respiratory outcomes

    by Lorenzo Zanetto, Luca Bonadies, Sabrina Salvadori, Enrico Valerio, Elena Priante, Daniel Nardo, Victoria Niklas, Daniele De Luca, Eugenio Baraldi

    Survival of extremely preterm infants has improved owing to advances in perinatal and neonatal care. However, bronchopulmonary dysplasia (BPD) has remained unabated, and research into preventive measures for the broader spectrum of prematurity-associated lung disease (PLD) has met with limited success. We summarize emerging therapeutic strategies with the potential to favorably influence the lifelong trajectory of lung health of preterm infants, especially the most immature. This narrative review examines recent preclinical and clinical studies on therapies for BPD prevention, focusing on mechanism-based interventions, biologic strategies, and innovative translational tools. Preclinical evidence converges on actionable targets in alveolarization, inflammatory pathways, redox and mitochondrial homeostasis, vascular and matrix remodeling. Novel molecules and drug-repurposing strategies are being tested in animal models, while patient-derived platforms may enable personalized therapeutic approaches. Mechanism-based approaches are progressing through Phase 1–2 clinical trials; pending efficacy analyses, insulin-like growth factor-1 replacement may become the first pharmacological therapy specifically approved to reduce or attenuate BPD. In parallel, cell-based therapies and extracellular vesicle strategies offer a complementary paradigm, acting through pleiotropic biological reprogramming of the injured lung. Ethical-regulatory complexity and the challenges of standardizing and scaling cell-based and cell-free therapies may limit clinical translation. Conclusion : A growing repertoire of therapies for BPD holds promise for modifying early respiratory illness and the long-term burden of PLD. Realizing this potential will benefit from both mechanism-informed combinatorial approaches and pleiotropic strategies, supported by patient-derived translational tools and adequately powered efficacy evaluations. Equally essential are tailored neonatal-first regulatory pathways linking the continuum of BPD to the later respiratory morbidity of PLD, a life-course condition with significant public health relevance beyond the neonatal period. What is Known: • Bronchopulmonary dysplasia (BPD) is the current clinical and regulatory endpoint for neonatal pulmonary therapies .• BPD definitions capture the most severe manifestations of prematurity-associated lung disease (PLD), a broader continuum of respiratory morbidity reaching into adulthood; attenuating BPD may improve the whole spectrum of PLD . What is New: • Therapies targeting alveolar, inflammatory, oxidative, vascular, and remodeling pathways are in clinical development; pending late-stage trials, IGF-1 replacement may become the first disease-modifying therapy to reduce BPD .• Novel targets, experimental platforms, and repurposed drugs hold promise for precision therapies in preterm infants .

  • The Evolving Knowledge on Primary Hemostasis in Neonates

    by Lorenzo Zanetto, Elena Campello, Mariella Magarotto, Stefano Sartori, Daniela Regazzo, Maurizio Muraca, Eugenio Baraldi, Paolo Simioni

    Neonatologists spend considerable effort with the aim of preventing neonatal bleeding. Traditionally, platelet failure has been widely considered a crucial determinant of neonatal hemorrhage. However, recent research challenges this view and suggests that platelet hyporeactivity may be part of a carefully balanced hemostatic system. This review explores the broader process of primary hemostasis in both term and preterm infants, beyond platelet function alone, integrating evidence from in vitro, laboratory, and point-of-care studies. Overall, studies raise concerns about the possible contribution of platelet dysfunction to an increased bleeding risk, especially in preterm infants. The clinical relevance of these findings remains uncertain, owing to methodological heterogeneity and the limited correlation with meaningful outcomes. Although platelet hyporeactivity has been largely attributed to a developmental impairment, it might also depend on prevailing up-regulated inhibitory pathways. Nevertheless, functional differences in plasma proteins provide enhanced adhesive capacities, supporting platelet-subendothelium interaction, further facilitated by higher hematocrit levels. Molecular explanations for platelet singularities are being uncovered thanks to omics studies. Advanced technologies such as microfluidics are enabling the study of cross-talking endothelium and platelets. Yet, the details of the interactions between platelets, erythrocytes, and white blood cells remain to be elucidated in the setting of developmental hemostasis. Emerging evidence on distinct pathways driving a lower pro-inflammatory tendency of the neonatal milieu might explain the poorer outcomes of those preterm infants receiving multiple transfusions of adult blood products. Awareness of the unique equilibrium of neonatal primary hemostasis calls for further research into the impact of neonatal therapies on hemostatic balance.

  • Open Access

    Singing to the newborn brain uncovers early traces of specialized neural networks

    by Caterina Marino, Jessica Gemignani, Léo Varnet, Lorenzo Zanetto, Eugenio Baraldi, Judit Gervain

    Song, a human cultural universal, fuses music and speech into a single auditory signal, one of the first among infants’ auditory experiences. While parents sing to their babies in all human cultures, we still know little about how this experience shapes babies’ perception abilities and their neural correlates. This work, therefore, investigates how the newborn brain processes song compared to its two components, speech and hummed melody. Specifically, we test the hypothesis that by regularizing the rhythm of speech, song may support language acquisition. Using functional near-infrared spectroscopy (fNIRS), we found that newborns’ (n = 40) showed stronger responses for both speech and song in the right temporoparietal regions than activation triggered by humming. Despite their clear acoustic distinctions, no significant differences were observed between the neural response of speech and song. This suggests that singing, just like speech, may represent a salient input for the newborn brain, potentially supporting early speech perception and language development.


  • Open Access

    Bronchopulmonary dysplasia and extremely preterm birth: time for a broader perspective on long-term outcomes

    by Luca Bonadies, Lorenzo Zanetto, Valentina Agnese Ferraro, Laura Moschino, Alberto Papi, Eugenio Baraldi

    Bronchopulmonary dysplasia is a hallmark respiratory complication of prematurity and remains a major health determinant of individuals born very preterm. Its impact, however, extends far beyond the neonatal period and far beyond the lungs. Children, adolescents and adults born very preterm often follow diverse developmental trajectories that diverge from typical postnatal growth. These trajectories often display early airflow limitation, as well as features of increased cardiovascular vulnerability and altered multisystemic profiles. Although common respiratory labels such as asthma are often applied to these patients, evidence highlights distinct pathobiological mechanisms rooted in arrested alveolar and vascular growth, with a possible contribution from persistent airway inflammation and oxidative stress. Extrapulmonary involvement, including cardiovascular, neurodevelopmental, neurosensory, renal and metabolic domains, further shapes long-term outcomes and should be systematically integrated into long-term monitoring. Yet, despite improving survival and growing recognition of this multisystemic burden, current evidence remains insufficient to design a dedicated, holistic, multidisciplinary follow-up programme tailored to the diverse subgroups of preterm-born individuals. Increasing awareness among healthcare professionals of the long-term implications of prematurity is essential to ensure that these patients receive appropriate and coordinated attention. Emerging lines of research, spanning new preventive and therapeutic options, advanced imaging, mechanistic studies, and long-term cohort designs, hold promise in elucidating the biological determinants of disease. Integrating these insights into clinical pathways, together with sustained implementation of family-centred care models, will be crucial to optimise organ function trajectories, delay deterioration and ultimately improve the quality of life of the growing population of survivors of prematurity.


  • Top Cited Papers
    Open Access

    Lung aeration and gas exchange in preterm infants developing moderate-to-severe bronchopulmonary dysplasia: a multicentre prospective study from the PATH-BPD cohort

    by Daniele De Luca, Luca Bonadies, Costanza Neri, Barbara Loi, Teresa Maria Silva-Garcia, Guillermo Ramos Noguera, Laura Vivalda, Giulia Res, Maria de Las Nieves Cidoncha-Fuertes, Carlos Baena-Palomino, et al.


  • Open Access

    Reply: Lung organoids: a new frontier in neonatology and paediatric respiratory medicine

    by Lorenzo Zanetto, Luca Bonadies, Raquel Moll-Diaz, Jeffrey Beekman, Maurizio Muraca, Michela Pozzobon, Eugenio Baraldi

    Sustainable development of neonatal and paediatric lung organoid research requires effective regulatory and collaborative frameworks. Ethically compliant tissue sources should be prioritised; robust ethical governance on sensitive sources is essential. https://bit.ly/4b9qeLf

  • Open Access

    Early prediction of bronchopulmonary dysplasia by urinary metabolomics: a case–control study

    by Luca Bonadies, Serena Calgaro, Matteo Stocchero, Paola Pirillo, Gabriele Poloniato, Lorenzo Zanetto, Laura Moschino, Giuseppe Giordano, Eugenio Baraldi

    Objective Bronchopulmonary dysplasia (BPD), the most frequent complication of extreme preterm birth, lacks not only of a comprehensive definition but also of effective treatments and predictive tools. Metabolomics is a valuable tool to unravel the underlying pathogenetic pathways of diseases and identify possible early markers. The objective of this study was to find metabolic signatures of subsequent BPD development, defined and stratified as per Jobe and Bancalari 2001 NHICD Consensus. Methods In this observational case–control study, we initially enrolled 161 very preterm unmatched infants, collected their urine samples during the first 24 hours of life and performed metabolomics evaluations on these samples. Patients were then followed until 36 weeks postmenstrual age. To reduce the influence of gestational age and other confounders on metabolome, we applied a nested case–control matching procedure that allowed the selection of 25 BPD cases and 25 non-BPD controls. Results Multivariate and univariate data analysis led to the recognition of 17 metabolites related to BPD development in the first day of life, of which three were identified: L-Glutamic acid (p value=0.038), o-Hydroxyphenylacetic acid (p=0.039), L-Homoserine (p value=0.020). Some of these metabolites are known to play a role in the protection against oxidative stress and/or inflammatory response, two of the most known factors involved in BPD pathogenesis. In particular, L-Glutamic acid and its ionic form glutamate were increased in infants developing BPD suggesting a role as promising marker of the disease. Conclusions Our findings pave the way to better characterise early origin of BPD from a metabolic point of view towards a better biological framework of the disease and, eventually, its prediction and possible new treatments.


  • Open Access

    Metabolomic Patterns at Birth of Preterm Newborns with Extrauterine Growth Restriction: Towards Putative Markers of Nutritional Status

    by Marta Meneghelli, Giovanna Verlato, Matteo Stocchero, Anna Righetto, Elena Priante, Lorenzo Zanetto, Paola Pirillo, Giuseppe Giordano, Eugenio Baraldi

    Background: Nutrition is of paramount importance during early development, since suboptimal growth in this period of life is linked to adverse long- and mid-term outcomes. This is particularly relevant for preterm infants, who fail to thrive during the first weeks of life and develop extrauterine growth restriction (EUGR). This group of premature babies represents an interesting population to investigate using a metabolomic approach to optimize nutritional intake. Aims: To analyse and compare the urinary metabolomic pattern at birth of preterm infants with and without growth restriction at 36 weeks of postmenstrual age or at discharge, searching for putative markers of growth failure. Methods: We enrolled preterm infants between 23 and 32 weeks of gestational age (GA) and/or with a birth weight <1500 g, admitted to the Neonatal Intensive Care Unit (NICU) at the Department of Women’s and Children’s Health of Padova University Hospital. We collected urinary samples within 48 h of life and performed untargeted metabolomic analysis using mass spectrometry. Results: Sixteen EUGR infants were matched with sixteen non-EUGR controls. The EUGR group showed lower levels of L-cystathionine, kynurenic acid, L-carnosine, N-acetylglutamine, xanthurenic acid, aspartylglucosamine, DL5-hydroxylysine-hydrocloride, homocitrulline, and L-aminoadipic acid, suggesting a lower anti-inflammatory and antioxidant status with respect to the non-EUGR group. Conclusions: Metabolomic analysis suggests a basal predisposition to growth restriction, the identification of which could be useful for tailoring nutritional approaches.